Table 2 Univariate analyses of clinical-pathological parameters for the prediction of cancer-specific survival, locoregional control and recurrence-free survival

Sex

 Male

1

1

1

 Female

1.24 (0.73–2.10)

1.08 (0.65–1.79)

1.01 (0.62–1.64)

Age at diagnosis

 < 60

1

1

1

 > 60

0.97 (0.60–1.59)

1.02 (0.65–1.59)

0.98 (0.64–1.49)

Smoking status

 Former or never

1

1

1

 Current

2.33 (1.31–4.14)

2.19 (1.30–3.68)

2.34 (1.43–3.82)

Alcohol consumption

 Former or never

1

1

1

 Current

1.73 (1.06–2.83)

1.90 (1.20–3.01)

1.88 (1.23–2.89)

Tumor grade

 G 1/2

1

1

1

 G 3/4

0.75 (0.46–1.22)

0.72 (0.46–1.12)

0.71 (0.47–1.08)

Tumor stage

 T 1/2

1

1

1

 T 3/4

3.53 (1.88–6.61)

4.99 (2.56–9.71)

3.62 (2.08–6.32)

Nodal involvement

 N0

1

1

1

 N+

1.55 (0.62–3.89)

1.21 (0.56–2.63)

1.42 (0.66–3.07)

Surgery

 Yes

1

1

1

 No

0.26 (0.14–0.46)

0.19 (0.11–0.35)

0.26 (0.16–0.42)

Induction chemotherapy

 Yes

1

1

1

 No

1.81 (1.05–3.10)

1.77 (1.08–2.88)

1.86 (1.18–2.94)

Concomitant chemotherapy

 Yes

1

1

1

 No

1.04 (0.61–1.77)

1.16 (0.69–1.93)

1.01 (0.64–1.61)

Platelet count (G/L)

 Median (mean ± SD)

1.004 (1.002–1.006)

1.004 (1.002–1.006)

1.003 (1.001–1.005)

MPV (fL)

 Median (mean ± SD)

0.85 (0.74–0.98)

0.86 (0.74–0.99)

0.87 (0.76–0.996)